Gals Bio

Problem/Need: In 2024, 1 million women were diagnosed with cancer, and 300,000 died (). Women’s diagnostics remain late, painful, and costly, despite vaginal secretions containing numerous biomarkers for improved health monitoring and early diagnostics. This reality highlights the urgent need for innovative, accessible, personalized, solutions to transform women’s health outcomes. Solution: Tulipon is the first of a series of Fem-Wearable devices developed by Gals Bio. It provides menstruators with easy access to new biomarkers within their monthly bleeding, enabling personalized, early health monitoring and screening from home with lab-level accuracy. Additionally, Tulipon offers worry-free, holistic monthly bleeding management. Target Markets: EU & US Looking for business opportunities in: Funding, Market Access, Research, Corporation, logistics, sales, manufacturing, Mentor Technology Readiness Level: TRL 8 Industrialization Contact info: Eng. Hilla Shaviv hilla@galsbio.com